Day 1 - 2023 agenda. The 2024 agenda will be published soon. - CET/CEST (Cent Europe Summer, GMT+2)
Day 1 - 2023 agenda. The 2024 agenda will be published soon. - CET/CEST (Cent Europe Summer, GMT+2)
Location: Exhibit Hall Stage
Learn everything you need to know to power up your partnering! This session is for delegates new to partnering. In this workshop, we will go over what you can expect out of partnering and what others will expect from you. We will provide an overview of the platform and discuss principles around timing and best practices to get the most out of partneringONE. Come away from the session with a clear understanding of what you can do to generate the best return on investment from partnering, at this and future events.
Location: Room Stockholm
- Claire Macht - Portfolio Director, Europe, EBD Group
- David Thomas - SVP, Industry Research, Biotechnology Innovation Organization (BIO)
- Roland Weigert - State Secretary, Ministry of Economic Affairs, Regional Development and Energy
- Ralf Huss - Managing Director, BioM Biotech Cluster Development GmbH
Location: Room Stockholm
The opening plenary session will explore the dynamic landscape of the biopharmaceutical industry, highlighting global trends that are shaping the next wave of innovation. Leading experts will discuss emerging technologies, regulatory shifts, and market forces, providing insights into the future of biopharma and its potential impact on healthcare.
- Daniel Chancellor - Thought Leadership and Consulting Director, Citeline
- Isma Hachi - Director, IQVIA
- Alexandra Zemp - Partner, McKinsey & Company
Location: Room Stockholm
The emergence of AI technologies provides immense potential to revolutionize the life science landscape. It equips the industry with new tools and approaches for drug discovery, diagnostics, personalized medicine and patient care. This session brings together key stakeholders involved in the entire value chain, who will discuss and evaluate the transformative potential and regulatory and ethical challenges of AI, whilst sharing their personal experiences and tapping into the future of the AI.
- Simon Turner - Partner, Sofinnova Partners
- Najat Khan, Ph.D. - Chief Data Science Officer and Global Head, Strategy, Portfolio & Operations, R&D, Janssen Pharmaceutical Companies of Johnson & Johnson
- Thomas Clozel - CEO, OWKIN
Location: Exhibit Hall Stage
Learn everything you need to know to power up your partnering! This session is for delegates familiar with partnering who want to take their partnering practice to the next level. This session will go over specific tools and top tips for collaborating with colleagues, saving time, as well as increasing response rates and acceptance rates. Come away from the session with a clear understanding of how partneringONE can support your company to maximize ROI from partnering, at this and future events.
Location: Room Stockholm
Auditing the strength of pharma pipelines and identifying partnering opportunities
- Mike Ward - Global Head of Thought Leadership, Decision Resources Group, part of Clarivate
- Nisha Nanda - Group VP, Business Development, Eli Lilly and Company
- John Copeland - Head of Commercial BD&L, MSD International
- Vincent Ruland - Head of R&D Strategy, Portfolio & Operations, Bayer Pharmaceuticals
- Nathalie ter Wengel - European Lead Worldwide Business Development, Pfizer
Location: Room Barcelona
In conversation with market leading Eli Lilly and Company, this session uncovers the latest trends and market size of the therapeutic area. The discussion will also highlight the story behind the discovery (and commercialization) of the novel drug and why the therapy is thriving in uncertain times, creating further opportunity in the industry.
- Melanie Senior - Senior Writer & Analyst, Nature Portfolio; Evaluate Pharma
- Axel Haupt - SVP, Early Clinical Investigation for Diabetes & Obesity and Complications, Eli Lilly and Company
Location: Room San Sebastian
13:00 – 13:15 Algen Biotechnologies Drug Discovery & Development
13:15 – 13:30 Aptah Bio Inc. Drug Discovery & Development
13:30 – 13:45 NanoTemper Technologies GmbH Drug Discovery & Development
13:45 – 14:00 Rejuvenate Biomed Drug Discovery & Development
14:00 – 14:15 ANeuroTech CNS/Neurology
14:15 – 14:30 Mecoxcuremed Drug Delivery
14:30 – 14:45 ReCode Therapeutics Drug Delivery
14:45 – 15:00 AULBIO Diabetes
15:00 – 15:15 Inhalon BioPharma Drug Delivery
Location: Exhibit Hall Stage
This session delves into the rapidly evolving landscape of the life sciences industry. As new technologies and players disrupt the traditional pharma model, the session highlights how Munich has become a thriving hub of innovation in biotech and life sciences. With its rich ecosystem of 250 life sciences companies, top-tier academic institutions, active VC community, and tech giants' presence, Munich serves as an exemplar of industry collaboration and symbiosis. The session explores the vital role of such ecosystems in tackling global challenges, particularly in the context of the recent COVID-19 pandemic. By hosting BIO-Europe, Munich brings together key stakeholders and experts to foster innovation, emphasizing the importance of cooperation and networking in delivering efficient, life-changing innovations to patients worldwide.
- Julia Groß - Editor, Focus Money
- Laura Lane - VP - Venture Sciences (Europe Head), Eli Lilly and Company
- Ralf Huss - Managing Director, BioM Biotech Cluster Development GmbH
- Heinrich Moisa - President & Managing Director, Novartis Germany
- Hubert Birner - Managing Partner, TVM Life Science Management GmbH
Location: Exhibit Hall Stage
Experience how a few breaths and stretches can de-stress you in just a few minutes.
Take a moment to exhale and move your body.
Calm your mind and feel the difference.
These sessions are designed to refresh your body and mind so you can get through a full conference day with more ease.
Open to all, without prerequisites.
Standing and seated (chair) exercises only.
Location: Room Stockholm
The recent spotlight on the use of AI in the life sciences has led to questions around the potential and ‘readiness’ of various AI platforms to drive efficiencies and productivity in target discovery, shrink development timelines and reduce attrition. This session explores how pharma and biotech companies are currently implementing AI across both internal R&D as well as to support external innovation strategy and business development. Ultimately the objective will be to begin to gauge how continued development and validation of AI approaches may ultimately transform the hunt for new breakthrough therapies.
- Ed Saltzman - Senior Strategic Advisor, Lumanity
- Najat Khan, Ph.D. - Chief Data Science Officer and Global Head, Strategy, Portfolio & Operations, R&D, Janssen Pharmaceutical Companies of Johnson & Johnson
- Richard Law - CBO, Exscientia
- Michelle Chen - CBO, Insilico Medicine
- Matthias Müllenbeck - SVP, Head Global Business Development & Alliance Management, Merck KGaA
Location: Room Stockholm
This fireside chat offers a unique opportunity to learn from a professional who has successfully navigated the transition from being a pharmaceutical executive to a venture capitalist and unravels the pivotal role venture capital plays in shaping the future of healthcare.
- Ed Saltzman - Senior Strategic Advisor, Lumanity
- Nigel Sheail - Venture Partner, Versant Ventures
Location: Exhibit Hall Stage
Love it or hate it - The European Pharmaceutical Legislation is going to redefine the business model of biotechnology in Europe. This panel will discuss what the legislation brings, its potential impact on businesses and what needs to be done to change the legislation in its journey to a final version, that it works for both, the biotech ecosystem, maintaining innovation pipelines, and patients.
- Claire Skentelbery - Director General, EuropaBio
- Daniel Steiners - Managing Director & General Manager Pharmaceutical Business Germany, Bayer Vital GmbH
Location: Room Barcelona
The panelists will cover how the power of data in the field of rare diseases has ushered in a new era of personalized medicine. By harnessing the insights gained from genomics, data sharing, AI, and other technological innovations, researchers and healthcare providers can develop more accurate diagnoses, tailored treatments, and improved outcomes for individuals with rare diseases.
- Lucie Ellis-Taitt - Executive Director - In Vivo, Citeline
- Lori Badura - VP Head of Global Partnering Rare Disease and Neuroscience, IPSEN
- Prof. Dr. med. Christoph Klein - Director, Care-for-Rare Foundation
- Eric Mertz - SVP Head of International Business Development & Strategic Delivery Management - Pharma, CENTOGENE
Location: Exhibit Hall Stage
Join the Quarteto Mystico orchestra who demonstrate how poor and positive leadership, along with weak and strong communication, impacts the performance of a team. Understand the importance of the supportive team and find out if being either a hierarchical, old-school or empathic leader is the secret to success is this new era of the life sciences.
- Stephanie Oestreich - Managing Director, MMRF
Location: Room San Sebastian
15:30 – 15:40 Biotts SA Drug Delivery
15:40 – 15:50 AlgoTx Pain Management
15:50 – 16:00 Terrapeutics Pharma Drug Discovery & Development
16:00 – 16:10 OncoLize BV Oncology
16:10 – 16:20 THERAtRAME Oncology
16:20 – 16:30 CARTemis Therapeutics GmbH Oncology
16:30 – 16:40 National Cancer Center Oncology
16:40 – 16:50 Protea Technologies & Tools
16:50 – 17:05 FunPep Co., Ltd. Technologies & Tools
17:05 – 17:20 VALANX Biotech GmbH Technologies & Tools
17:20 – 17:35 STALICLA SA CNS/Neurology